Research and Markets: Five Year Sales Forecasts for the Pharmaceutical Company - Sanofi-Aventis

Business Wire, May 15, 2006

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c36982) has announced the addition of the Espicom Business Intelligence Ltd report: sanofi-aventis Pharmaceutical Company Intelligence Report to their offering.

Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Principal Operating Results

Latest Results

EXECUTIVE SUMMARY

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

APPENDIX 1 - FINANCIA L PERFORMANCE

APPENDIX 2 - KEY CORORATE EVENTS

APPENDIX 3 - KEY AGREEMENTS

APPEN DIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINTVENTURES

APPEN DIX 6 - PRODUCT IN DEX

Summary

sanofi-aventis ranks third amongst research-based pharmaceutical companies, behind Pfizer and GlaxoSmithKline. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

sanofi-aventis was formed in August 2004, when Sanofi-Synthelabo acquired control of Aventis. Subsequently, on 31st December 2004, Aventis merged with and into sanofi-aventis, with sanofi-aventis as the surviving company. With total revenues of over EUR 27 billion in 2005, the combined entity ranks third amongst research-based pharmaceutical companies behind Pfizer and GlaxoSmithKline.

sanofi-aventis is focused on two core areas, pharmaceuticals (principally prescription drugs) and human vaccines. Within the pharmaceutical area, sanofi-aventis is active in the following therapeutic areas: Cardiovascular/Thrombosis, Metabolism, Oncology, Central Nervous System and Internal Medicine (which includes Respiratory/Allergy, Urology, Arthritis/Osteoporosis and Anti-infectives).

Current Growth Drivers

In the cardiovascular field, Plavix is sanofi-aventis' second best selling product and has demonstrated strong year-on-year sales increases. The recent approval in Japan for the treatment of stroke (January 2006) will further boost sales and is expected to expand sanofi-avenits' profile within this market.

Lantus has achieved remarkable year-on-year growth in an increasingly competitive field, with its once-daily dosing setting it apart from its competitors. The US launch of Lantus in combination with Apidra, scheduled for the first quarter of 2006, is anticipated to further bolster sales, allowing it to make significant gains in the metabolic market.

Sales of Actonel for use in the prevention and treatment of postmenopausal osteoporosis and corticosteroid-induced osteoporosis, are showing a steady increase. Estimated peak sales of this product are forecast at over US$1 billion.

sanofi pasteur (sanofi-aventis' vaccines subsidiary) is a world leader in the development and marketing of vaccines. 2005 saw three successful launches: Decavac, Menactra and Adacel. sanofi pasteur also has the ability to exploit the expanding influenza market. The following launches are set to drive growth in 2006: Pediacel (polio, pertussis/Hib)' ProQuad (measles, mumps, Rubella and Varicella); Gardasil (Herpes and genital infections); RotaTeq (rotavirus infections); Zostavax (Zoster) and Menactra (meningitis).

This company report provides

Latest Results

A brief review of the latest report results

Executive Summary

At a glance understanding of the major trends and events affecting the company

Financial Analysis (current year)

Detailed P&L and investment review of the latest full year performance

Company Strategy

Where's the company going and how does it plan getting there?

Product/R&D Pipeline

Highly detailed monographs organised by therapeutic category. Also covers R&D strategy/pipeline and provides 5-year sales forecasts to 2010 for major launched products where available

Appendices

5-year financial assessment

Key corporate events

Key agreements

Infrastructure

Major pharmaceutical subsidiaries/joint ventures

Product index

Companies Mentioned Include:

aaiPharma - Acambis plc - Ajinomoto Co Inc - Altana Pharma AG - Amgen - Astellas Pharma Inc - Astex Technology - Atrix Laboratories Inc - Bristol-Myers Squibb - Celera Genomics/Axys Pharmaceuticals - Cephalon Inc - Chiron Corporation - Ciphergen Biosystems - Coley Pharmaceutical Group Inc. - Crucell NV - Daiichi Sankyo - Dainippon Sumitomo Pharma - Debiopharm SA - Eli Lilly - GlaxoSmithKline - IDM Pharma Inc - ImmunoGen Inc - King Pharmaceuticals Inc - Millennium Pharmaceuticals Inc - Novo Nordisk - Pfizer - Prasco Laboratories - Procter & Gamble - Regeneron Pharmaceuticals Inc - Roche/Genentech - SAS Institute - Shionogi - Teva Pharmaceutical Industries Ltd - VaxGen Inc - Zealand Pharmaceuticals A/S